NASDAQ:DMAC DiaMedica Therapeutics (DMAC) Stock Price, News & Analysis $8.79 -0.54 (-5.79%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$8.78 0.00 (-0.06%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About DiaMedica Therapeutics Stock (NASDAQ:DMAC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get DiaMedica Therapeutics alerts:Sign Up Key Stats Today's Range$8.11▼$9.2250-Day Range$6.47▼$10.7752-Week Range$5.24▼$11.00Volume214,091 shsAverage Volume211,040 shsMarket Capitalization$474.04 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingHold Company Overview DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for serious diseases, with a focus on preeclampsia and neurological conditions. Its lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1, an enzyme involved in regulating blood flow. DiaMedica is investigating DM199 for acute ischemic stroke and preeclampsia; it remains an investigational drug and is not approved for commercial use. The company is headquartered in Minneapolis, Minnesota, and conducts clinical development of its therapies.AI Generated. May Contain Errors. Read More DiaMedica Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreDMAC MarketRank™: 1.817824377455 of 5 starsDiaMedica Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 724th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingDiaMedica Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDiaMedica Therapeutics has a consensus price target of $12.00, representing about 36.5% upside from its current price of $8.79.Amount of Analyst CoverageDiaMedica Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about DiaMedica Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for DiaMedica Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DiaMedica Therapeutics is -11.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DiaMedica Therapeutics is -11.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDiaMedica Therapeutics has a P/B Ratio of 8.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.80% of the float of DiaMedica Therapeutics has been sold short.Short Interest Ratio / Days to CoverDiaMedica Therapeutics has a short interest ratio ("days to cover") of 24.77, which indicates bearish sentiment.Change versus previous monthShort interest in DiaMedica Therapeutics has recently decreased by 4.25%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDiaMedica Therapeutics does not currently pay a dividend.Dividend GrowthDiaMedica Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.02 News SentimentDiaMedica Therapeutics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for DiaMedica Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for DMAC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added DiaMedica Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, DiaMedica Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.00% of the stock of DiaMedica Therapeutics is held by insiders.Percentage Held by Institutions10.12% of the stock of DiaMedica Therapeutics is held by institutions.Read more about DiaMedica Therapeutics' insider trading history. Receive DMAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DiaMedica Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DMAC Stock News HeadlinesDiaMedica Therapeutics (NASDAQ:DMAC) Stock Rating Lowered by Wall Street ZenNovember 14 at 1:43 AM | americanbankingnews.comDiaMedica Therapeutics Inc. (DMAC) Q3 2026 Earnings Call TranscriptNovember 13 at 7:11 PM | seekingalpha.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 15 at 1:00 AM | Behind the Markets (Ad)DiaMedica expects cash to fund operations into Q4 2027 as ReMEDy2 interim analysis approaches in Q1 2027November 13 at 7:11 PM | seekingalpha.comDiaMedica (DMAC) Q3 2026 Earnings Call TranscriptNovember 13 at 7:11 PM | fool.comDiaMedica Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business HighlightsNovember 12 at 5:00 PM | businesswire.comDiaMedica Therapeutics (DMAC) Set to Release Earnings on ThursdayNovember 11, 2026 | americanbankingnews.comDiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026November 5, 2026 | finance.yahoo.comSee More Headlines DMAC Stock Analysis - Frequently Asked Questions How have DMAC shares performed this year? DiaMedica Therapeutics' stock was trading at $7.96 at the start of the year. Since then, DMAC stock has increased by 10.4% and is now trading at $8.79. How were DiaMedica Therapeutics' earnings last quarter? DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) posted its quarterly earnings data on Thursday, November, 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.00. Read the conference call transcript. When did DiaMedica Therapeutics IPO? DiaMedica Therapeutics (DMAC) raised $18 million in an IPO on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO. Who are DiaMedica Therapeutics' major shareholders? DiaMedica Therapeutics' top institutional investors include State Street Corp (1.22%), AWM Investment Company Inc. (0.12%) and Tocqueville Asset Management L.P. (0.07%). Insiders that own company stock include Jan Stahlberg and Koch Thomas Von. View institutional ownership trends. How do I buy shares of DiaMedica Therapeutics? Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DiaMedica Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that DiaMedica Therapeutics investors own include NIO (NIO), Palantir Technologies (PLTR), Tesla (TSLA), NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), Novavax (NVAX) and Viking Therapeutics (VKTX). Company Calendar Last Earnings11/12/2026Today11/15/2026KOL event11/24/2026Study update11/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 DMAC's financial health is in the Green zone, according to TradeSmith. DMAC has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DMAC CIK1401040 Webwww.diamedica.com Phone(763) 496-5454FaxN/AEmployees35Year Founded2000Price Target and Rating Average Price Target for DiaMedica Therapeutics$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+36.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$32.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-85.26% Return on Assets-75.76% Debt Debt-to-Equity RatioN/A Current Ratio6.72 Quick Ratio6.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book8.14Miscellaneous Outstanding Shares53,930,000Free Float51,230,000Market Cap$474.04 million OptionableOptionable Beta0.95 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:DMAC) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
